- Published on
Trump wants Big Pharma to split MMR vaccine; Big Pharma thinks it's idiotic
- Authors
- Name
- DeepHorus
President Donald Trump’s executive order on Monday, which seeks to overhaul federal childhood vaccine policy and split the combined MMR vaccine into separate shots, has drawn immediate and sharp condemnation from public health groups, medical organizations, and now the pharmaceutical industry. The American Academy of Pediatrics called the measure “not only disheartening but dangerous,” while other experts labeled it “unscientific” and “false and misleading.” The order, championed by Health Secretary Robert F. Kennedy Jr., who has no medical background, represents the administration’s latest push against established vaccine science.
The backlash was swift, particularly from the American Academy of Pediatrics, which is already leading a lawsuit against earlier federal vaccine recommendation changes under Trump and Kennedy. In March, that lawsuit, joined by other medical groups, won a temporary injunction reversing most of those changes. Now, the new order threatens to undo decades of progress in pediatric immunization.
A central and highly impractical provision requires splitting the measles, mumps, and rubella (MMR) combination vaccine into three separate injections. The MMR vaccine is normally administered in two doses, meaning children would face six shots instead of two. Yet individual vaccines for measles, mumps, and rubella are not currently licensed or available in the United States.
To comply, pharmaceutical companies would need to invest heavily in developing, testing, and marketing entirely new vaccines—with no scientific justification. The existing combination vaccine has a proven record of safety, effectiveness, and convenience supported by decades of real-world data. Splitting it would increase cost, complexity, and the number of needle sticks without improving public health outcomes.
PhRMA, the leading trade group representing major drugmakers like GSK, Sanofi, Pfizer, Merck, Johnson & Johnson, and Novo Nordisk, issued a statement within hours of the order, asserting that the policy “debases America’s vaccine policy.” The industry’s rare public rebuke underscores how far the order departs from medical and scientific consensus.
Experts warn that the order could undermine vaccination rates and put children’s health at risk. By promoting false equivalencies between vaccines and unproven alternatives, it may confuse parents and erode trust in essential immunizations. The practical impossibility of procuring separate shots also threatens to delay or interrupt MMR coverage across the country.
Looking ahead, the order faces likely legal challenges from medical organizations and broad noncompliance from pharmaceutical manufacturers. Even if the administration persists, no company is expected to produce nonexistent single-antigen vaccines without multibillion-dollar investments and years of clinical trials. The episode highlights a deepening rift between the administration and the scientific community, with children’s health hanging in the balance.
